4 episodes
The Certara Market Access Channel Certara Evidence & Access
-
- Science
-
-
4.0 • 2 Ratings
-
Welcome to the Market Access Podcast, your expert briefing on the latest in Market Access and Health Economics in the Bio-Pharmaceutical Industries.
-
(4) Policy Briefing: A new agenda for CMS, the Biden White House, and a Democratic Congress
We're finally back with a new season for the Radar Podcast, pharma's flagship intelligence briefing on all things market access, real-world evidence, and payer strategy. This program is brought to you by the experts in Certara's global Evidence & Access practice.
In this episode, we're discussing the Biden administration's policy positions, the fate of Trump-era CMS proposals, and what the new majority in the 117th Congress will mean for the biopharma industry.
Your host for this week is Max Goldstein, Director of Business Development, speaking to Ulrich Neumann, Senior Director, Access and Commercial Strategy. For any questions on the topics discussed today, please contact ulrich.neumann@certara.com or download our latest whitepapers here: https://www.certara.com/evidence-access/us-managed-markets/key-trends-us-specialty/
---
Send in a voice message: https://podcasters.spotify.com/pod/show/market-access/message -
(3) The Part B IPI Model
In this episode, we're dissecting the US Administrations initiative to overhaul Medicare Part B drug reimbursement, incorporating international reference pricing.
Experts on call
Ulrich Neumann, Sr. Director, US Access ulrich.neumann@certara.com
Additional notes:
- We referenced the Implications of Pricing on Innovation which is thoroughly discussed in this article by USC's Darius Lakdawalla
Lakdawalla, Darius N. 2018. "Economics of the Pharmaceutical Industry." Journal of Economic Literature, 56 (2): 397-449.
DOI: 10.1257/jel.20161327
---
Send in a voice message: https://podcasters.spotify.com/pod/show/market-access/message -
(2) IDN and Pharma Collaborations
Listen in for this stakeholder panel on strategic collaborations with hospital & provider systems, IDNs and ACOs to bring value-based care to patients.
Experts on call
Shontelle Dodson, SVP, Astellas
Matt Portch, VP Sunovion,
Gergana Zlateva, VP Pfizer,
Terrill Jordan, CEO of the RCCA provider network
Ulrich Neumann, Sr. Director, Head US Access, Certara (ulrich.neumann@certara.com)
---
Send in a voice message: https://podcasters.spotify.com/pod/show/market-access/message -
(1): Outcomes Based Agreements: Deal or No Deal
In our first episode, we're shining a light on the next frontier for outcomes-based agreements (OBA). If we move beyond the initial excitement and PR, where does pharma stand on risk-sharing and innovative contracting?
Experts
Roman Casciano, GM, Analytica Laser & SVP, Market Access, HEOR and Real-world Evidence, Certara
Lee Stern, VP, Business Development, Certara Evidence & Access
Ulrich Neumann, Sr. Director, Head US Access, Certara (ulrich.neumann@certara.com)
---
Send in a voice message: https://podcasters.spotify.com/pod/show/market-access/message
Customer Reviews
Top Podcasts In Science